Botulinum toxin for cervical dystonia: addressing treatment failure and improving outcomes by Pena, Ashley B.
218 www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Neurologia i Neurochirurgia Polska
Polish Journal of Neurology and Neurosurgery
2020, Volume 54, no. 3, pages: 218–219
DOI: 10.5603/PJNNS.2020.0047
Copyright © 2020 Polish Neurological Society 
ISSN 0028–3843
INVITED EDITORIAL
Address for correspondence: Ashley B. Pena, Mayo Clinic Florida, 4500 San Pablo Rd S, 32224 Jacksonville, USA, e-mail: Pena.Ashley@mayo.edu
Botulinum toxin for cervical dystonia: addressing treatment 
failure and improving outcomes
Ashley B. Pena
Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA
ABSTRACT
Introduction. Cervical dystonia is a form of focal dystonia characterised by tilting and turning of the head and neck. This can 
cause significant disability in affected patients. Botulinum toxin injections are the mainstay of therapy. However, approximately 
30% of patients discontinue treatment.
Clinical reflections. Tyślerowicz et al. have provided a comprehensive review of the factors contributing to treatment failure. 
Such factors include appropriate identification of dystonia patterns, accurate injection of muscles, and addressing non-motor 
features of cervical dystonia.
Clinical implications. A systematic approach is needed to identify and address the potentially modifiable factors that contri-
bute to treatment failure.
(Neurol Neurochir Pol 2020; 54 (3): 218–219)
Cervical dystonia is a common form of focal dystonia. It 
can cause dystonic head tremor, impaired range of motion, 
and musculoskeletal pain, leading to significant functional 
disability for the patient [1]. 
Effective and well tolerated treatment options are the-
refore vital to preserve and restore functional status. Oral 
medications are notoriously ineffective in the treatment of 
cervical dystonia, and can present significant adverse effects. 
Botulinum toxin therapy has therefore become the mainstay of 
treatment due to its proven clinical efficacy and favourable side 
effect profile [2, 3]. However, approximately 30% of patients 
discontinue treatment with botulinum toxin injections [4]. 
Tyślerowicz et al. have presented a review of potential 
pitfalls in the treatment of cervical dystonia with botulinum 
toxin. In addition to providing a detailed analysis of reasons 
for botulinum toxin treatment failure, they have discussed 
strategies for optimising treatment  [5]. 
Assuring the correct diagnosis is the all-important first 
step in treating any neurological disorder. In the case of cer-
vical dystonia, this includes assessing for mimics, identifying 
comorbid movement disorders, and fully addressing secondary 
causes of cervical dystonia. There are a number of movement 
disorders with similar phenomenology that can mimic cervical 
dystonia. These include tic disorders, particularly dystonic 
tics for which additional behavioural and pharmacological 
therapies may be beneficial [6, 7]. Cervical dystonia can also 
be seen in the context of other movement disorders including 
Parkinson’s Disease and atypical parkinsonian disorders, 
which present additional symptomatology and disease pro-
gression that may affect treatment response [8].
Successful treatment with botulinum toxin requires proper 
identification of the pattern of dystonia. The classification 
system used to identify dystonic movements impacts upon 
which muscles are then targeted with botulinum toxin [9]. 
Tyślerowicz et al. emphasise the utility of the Col-Cap sche-
me for identifying the components of dystonic posturing [5]. 
Dystonic movements can include turning and tilting of the 
head and neck in the lateral and anterior-posterior planes. 
A combination of these abnormal postures is often seen [10]. 
Utilising techniques such as EMG guidance to assure proper 
placement of botulinum toxin injections may assist in this 
approach. The therapeutic response may also be improved 
by appropriately escalating the dose and the distribution 
of botulinum toxin injections within the targeted muscles 
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[11, 12]. Proper counselling of patients is an essential comple-
ment to this optimisation process. Patients who are unaware 
of the potential for optimisation with repeated injections may 
wrongly perceive botulinum toxin treatment to be ineffective, 
and thus prematurely discontinue treatment [4, 13]. 
For patients who have had a suboptimal response to 
botulinum treatment over a long period, considerations may 
include immunity to botulinum toxin and complications of 
cervical dystonia such as muscle contracture and fibrosis [5]. 
A frequently overlooked component of treatment response 
is the contribution of non-motor features associated with cer-
vical dystonia. These can include psychiatric disorders such as 
anxiety and depression, which can degrade quality of life and 
contribute to a subjective lack of improvement. Psychiatric 
symptoms appear to occur independently of the severity of mo-
tor symptoms, rather than as a consequence of motor symptoms 
[14, 15, 16]. As such, psychiatric symptoms do not demon-
strate response to the treatment of motor symptoms [17, 18]. 
This suggests that the treatment of psychiatric comorbidities 
could play an important role in improving quality of life in 
patients with cervical dystonia. 
Tyślerowicz et al. emphasise that a systematic approach 
is needed to examine the numerous potential contributors to 
botulinum toxin treatment failure [5]. Specific attention should 
be paid to addressing modifiable contributors. 
It is important to optimise botulinum toxin treatment not 
only to prevent patient disability and improve quality of life, 
but also to maximise treatment efficacy prior to pursuing more 
invasive treatment options such as deep brain stimulation or 
selective denervation procedures. 
In light of the wide array of contributors to botulinum to-
xin treatment failure outlined by this review, the development 
of a protocol-driven rehabilitative approach may be beneficial 
to augment the treatment of cervical dystonia.
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